Yasuko Nishimura
Osaka, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Efficacy and safety of fixed-duration venetoclax plus obinutuzumab in untreated Japanese CLL and SLL: a phase 2 study.
Journal: International journal of hematology
Published: August 20, 2025
A phase 2 study of ibrutinib with venetoclax in Japanese patients with untreated CLL and SLL.
Journal: International journal of hematology
Published: August 20, 2025
Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax.
Journal: International journal of hematology
Published: March 24, 2023
Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan.
Journal: Japanese journal of clinical oncology
Published: November 17, 2022
Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial.
Journal: International journal of clinical oncology
Published: May 04, 2022
Venetoclax in combination with azacitidine in Japanese patients with acute myeloid leukaemia: phase 1 trial findings.
Journal: Japanese journal of clinical oncology
Published: December 17, 2020
Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Journal: International journal of hematology
Published: May 07, 2020
Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance Therapy.
Journal: Inflammatory intestinal diseases
Published: October 23, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026